← Eichor
Study identifier: NCT05783466 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Dairy Lipids and Cardiometabolic Risk

Condition: Morbid Obesity  ·  Sponsor: Hospices Civils de Lyon

PhaseNA
Planned participants75
Who can joinAll sexes, 18 Years to 70 Years
Healthy volunteersNo

About this study

It is a randomized parallel arm intervention study in adults with severe obesity. The objective is to demonstrate that within a dietary handling for weight loss, the daily ingestion during 3 months of whole dairy products enriched with milk polar lipids or whole dairy products decreases to a greater extent fasting plasma apolipoprotein B concentrations than the daily ingestion of low-fat dairy products (control group). Metabolic parameters will be assessed before and after the 3-month intervention, both at fasting and in postprandial period after the consumption of standardized meals.

This description comes directly from the study's public registry record.

Talk to the study team

Emmanuel DISSE, Pr  ·  +33 4 78 86 14 89  ·  emmanuel.disse@chu-lyon.fr

MArie-Caroline MICHALSKI, Dr  ·  +33 4 26 23 61 71  ·  marie-caroline.michalski@inrae.fr

Always discuss trial participation with your own doctor first.

Locations (2)

Centre de Recherche en Nutrition Humaine Rhône-AlpesPierre-Bénite, FranceActive Not Recruiting
Centres Hospitalier Lyon Sud, Service d'Endocrinologie-Diabète-NutritionPierre-Bénite, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05783466